A new drug with fulvestrant for HR+/HER2- advanced breast cancer
Treatments studied
Part of Cancer, Skin clinical trials.
This trial tests a new investigational drug called BEBT-209 combined with fulvestrant (a hormone therapy) versus placebo with fulvestrant for people with a type of breast cancer that is hormone receptor-positive and HER2-negative. It is for those whose cancer has worsened after previous hormone therapy and has spread locally or to other parts of the body.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a woman 18 or older, and either postmenopausal or willing to take a drug to suppress ovarian function.
- Your breast cancer must be HR+ (hormone receptor-positive) and HER2-negative, confirmed by a recent biopsy.
- Your cancer must have grown during or within 12 months of finishing hormone therapy, or within 1 month of starting hormone therapy for advanced disease.
- You may have had up to one chemotherapy for advanced cancer, but no previous treatment with fulvestrant, everolimus, or CDK4/6 inhibitors.
- You must be in good general health, with adequate blood cell counts, kidney and liver function, and no uncontrolled heart conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug, HRS-6209, combined with other treatments for people with hormone receptor-positive, HER2-negative cancer. The goal is to see if the combination is safe and works well.
This trial tests a new drug, NTQ1062, combined with fulvestrant in people with a type of breast cancer called HR-positive, HER2-negative that has spread or come back. The study aims to see if this combination helps shrink or control the cancer.
This trial tests a new study medicine (PF-07248144) combined with fulvestrant in people with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has worsened after previous treatments. It may be an option if you've already tried a CDK4/6 inhibitor and endocrine therapy.
This trial tests a new drug called M1774 combined with fulvestrant for people with hormone receptor-positive, HER2-negative advanced breast cancer that has worsened after standard treatments. It aims to see if this combination can help when other therapies have stopped working.
This trial tests a new Bcl-2 inhibitor (BGB-21447) combined with other therapies for advanced HR+/HER2- breast cancer that has already been treated with hormone therapy and a CDK4/6 inhibitor. It aims to see if these combinations are safe and effective.
This trial tests a combination of two drugs—entinostat and fulvestrant—for women with a certain type of advanced breast cancer (HR-positive, HER2-negative) that has stopped responding to standard hormone therapy and a CDK4/6 inhibitor. The goal is to see if this combo can help shrink tumors or slow their growth.
Hear when a new HR+/HER2- Locally Advanced, Metastatic Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.